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Members of the transforming growth factor-b (TGF-b) superfamily participate in numerous biological phenomena in multiple
tissues, including in cell proliferation, differentiation, and migration. TGF-b superfamily proteins therefore have prominent roles
in wound healing, ﬁbrosis, bone formation, and carcinogenesis. However, the molecular mechanisms regulating these signaling
pathways are not fully understood. Here, we describe the regulation of bone morphogenic protein (BMP) signaling by Bat3 (also
known as Scythe or BAG6). Bat3 overexpression in murine cell lines suppresses the activity of the Id1 promoter normally
inducedbyBMPsignaling.Conversely,Bat3inactivationenhancestheinductionofdirectBMPtargetgenes,suchasId1,Smad6,
and Smad7. Consequently, Bat3 deﬁciency accelerates the differentiation of primary osteoblasts into bone, with a concomitant
increase in the bone differentiation markers Runx2, Osterix, and alkaline phosphatase. Using biochemical and cell biological
analyses, we show that Bat3 inactivation sustains the C-terminal phosphorylation and nuclear localization of Smad1, 5, and 8
(Smad1/5/8), thereby enhancing biological responses to BMP treatment. At the mechanistic level, we show that Bat3 interacts
with the nuclear phosphatase small C-terminal domain phosphatase (SCP) 2, which terminates BMP signaling by
dephosphorylating Smad1/5/8. Notably, Bat3 enhances SCP2–Smad1 interaction only when the BMP signaling pathway
is activated. Our results demonstrate that Bat3 is an important regulator of BMP signaling that functions by modulating
SCP2–Smad interaction.
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Members of the transforming growth factor-b (TGF-b) super-
family control a plethora of cellular responses, including cell
proliferation, stem cell renewal, differentiation, extracellular
matrix remodeling, and embryonic development.
1–3 TGF-b
superfamily proteins include the TGF-bs, activins, and bone
morphogenic proteins (BMPs). These molecules are ligands
thatengageacomplexcomposedoftypeIreceptorandtypeII
receptors to initiate intracellular signaling. This ligand-
dependent formation of the active receptor complex leads to
the phosphorylation of type I receptor by type II receptor.
Activated type I receptors in turn recruit speciﬁc receptor-
activated Smads (R-Smads), depending on the ligand.
Smad1, 5, and 8 (Smad1/5/8) are recruited in response
to BMP binding, whereas Smad2 and 3 are recruited in
response to TGF-bs and activins. Activated type I receptor
then phosphorylates a Ser–Ser–X–Ser (SSXS) motif in the
C-terminal region of the R-Smads, activating them. Activated
R-Smads in turn form hetero-oligomeric complexes with the
common mediator Smad4 (the Co-Smad), translocate to the
nucleus, and regulate transcription of their target genes.
Structurally, R-Smads contain Mad homology 1 (MH1) and
Mad homology 2 (MH2) domains, which are connected by a
linkerregion.TheCo-SmadalsocontainstheMH1,linker,and
MH2 domains but lacks the SSXS motif.
The ongoing discovery of an increasing number of
Smad phosphatases suggests that dephosphorylation is a
critical mechanism for terminating Smad activity. Protein
phosphatase 1A, magnesium-dependent, a-isoform (PPM1A)
mediates the C-terminal dephosphorylation of Smad2/3
4
and Smad1.
5 Additional Smad1 phosphatases include
pyruvate dehydrogenase phosphatase 1 and 2, and the small
C-terminal domain phosphatase (SCP) 1 and 2.
6,7 Dephosph-
orylation of Smad1 by any one of these phosphatases
attenuates BMP signaling. In contrast, SCPs can enhance
thetranscriptionalactivityofSmad2/3byremovinganinhibitory
phosphate moiety inthe linker region.
8 However, relatively little
is known about the signaling pathways that regulate Smad
dephosphorylation.
Bat3 (also called Scythe
9 or BAG6) was originally identiﬁed
as a gene located within the class III region of the human
major histocompatibility complex on chromosome 6.
10 Bat3
has been reported to regulate NK cell signaling,
11 histone
methylation,
12 and apoptosis in a variety of settings,
9,13–17
suggesting that Bat3 is a mediator in diverse signaling
Received 04.8.11; revised 26.9.11; accepted 11.10.11; Edited by A Stephanou
1Campbell FamilyInstitute forCancerResearch, OntarioCancerInstitute, UniversityHealthNetwork,Toronto, Ontario, Canada and
2DepartmentofMedical Biophysics,
University of Toronto, Toronto, Ontario, Canada
*Corresponding author: H Okada, Campbell Family Institute for Cancer Research, Ontario Cancer Institute, University Health Network, 620 University Avenue, Suite
7-706, Toronto, Ontario, Canada M5G 2C1. Tel: þ416 946 4538; Fax: þ416 204 2277; E-mail: hokada@uhnres.utoronto.ca
Keywords: Bat3/Scythe/BAG6; TGF-b; BMP; Smad; phosphorylation; phosphatase
Abbreviations: TGF-b, transforming growth factor-b; BMP, bone morphogenic protein; ALP, alkaline phosphatase; ALK, activin receptor-like kinase; SCP,
small C-terminal domain phosphatase
Citation: Cell Death and Disease (2011) 2, e236; doi:10.1038/cddis.2011.114
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
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targeting of tail-anchored proteins to the endoplasmic
reticulum
18,19 and in degradation of mislocalized and
misfolded proteins.
20,21 Relevant to our current study, Bat3
was reported to interact with TGF-b receptors and to enhance
TGF-b-induced expression of type I collagen (ColIA).
22
Although nuclear Bat3 appeared to be critical for this event,
the underlying molecular mechanism remains unclear.
In this study, we present evidence implicating Bat3 as a
negative regulator of BMP signaling. RNAi-mediated deple-
tionofBat3sustainsBMPtargetgeneinductionandenhances
BMP-mediated osteoblast differentiation. In the absence of
Bat3, C-terminal phosphorylation of Smad1/5/8 is markedly
prolonged. Atthe protein level, Bat3physically interacts with a
nuclear phosphatase, SCP2, that regulates Smad1/5/8
phosphorylation. In the presence of Bat3, the interaction of
SCP2 with Smad1 that is triggered by activation of BMP
signaling is increased. On the basis of our data, we propose a
model in which Bat3 regulates BMP signaling pathways by
modulating SCP2-mediated dephosphorylation of Smads.
Results
Bat3 is a suppressor of BMP signaling. Bat3 overexpression
in murine mesangial cells was reported to induce TGF-b target
genes, including ColIA.
22 However, the molecular mechanism
by which Bat3 regulates TGF-b signaling is a mystery. Neither
is it known whether Bat3 can regulate the functions of other
TGF-b superfamily members such as BMP. To address these
questions, we ﬁrst used a reporter system to examine whether
Bat3 can inﬂuence the transactivation activity of Id1,a n
immediate-early BMP target gene.
23 We co-transfected
U2OS human osteosarcoma cell line with separate constructs
expressing Bat3–Myc, an Id1–luciferase (luc) reporter gene, and
an HA-tagged, constitutively active (QD) form of a BMP receptor
(activin receptor-like kinase (ALK) 2-, ALK3- or ALK6-QD
24).
We found that, rather than enhancing BMP target gene
expression, Bat3 overexpression greatly suppressed the
Id1 promoter activity induced by all ALKs-QD (Figure 1a).
These data suggest that Bat3 negatively, rather than positively,
regulates BMP signaling.
To test whether Bat3 had a negative impact on BMP
signaling in a biological setting, we transfected C2C12 mouse
myoblast cells with small interfering RNA (siRNA) oligo
duplexes speciﬁc for mouse Bat3 (siBat3) or a control
scrambled siRNA (siControl; siCNT; Supplementary Figure 1A).
We cultured these cells with 100ng/ml BMP-2 for 3, 24, or
48h and examined mRNA levels of the BMP target genes Id1,
Smad6, and Smad7. Transcript levels of all these target genes
were comparable between control and Bat3-depleted cells
after 3h of BMP treatment (Figure 1b). However, higher levels
of all target gene mRNAs were observed in Bat3-depleted
cells compared with control cells after 24h BMP treatment.
This sustained induction of BMP target genes in Bat3-
depleted cells was even more prominent after 48h, whereas
transcript levels of all target genes in siCNT cells after 48h in
BMP were comparable to those in untreated cells (Figure 1b).
Similar results were obtained when primary osteoblasts were
isolated from wild-type (WT) or gene-targeted Bat3-deﬁcient
(Bat3
 / )m i c e
17 and treated with BMP-2 for 3 or 48h.
Enhanced induction of the same BMP target genes was
observed in extracts of BMP-treated Bat3
 /  osteoblasts at
48h compared with BMP-treated WT controls (Figure 1c).
These data further support our initial observation that Bat3
negatively regulates the induction of BMP target genes.
Bat3 inactivation sustains C-terminal phosphorylation
of Smad1/5/8. Although a previous report had indicated that
nuclear Bat3 could enhance TGF-b signaling,
22 our data
above suggested the opposite conclusion. We speculated
that Bat3 might have an indirect modulatory effect on the
function of nuclear components of BMP signaling.
Phosphorylation is a key means of regulating Smad
functions.
25 To determine the role of Bat3 in Smad
phosphorylation, we transfected C2C12 cells with lentivirus
expressing shRNA against Bat3 (shBat3) or control shRNA
(shCNT; Supplementary Figure 1B) and treated these cells
with 50ng/ml BMP-2 for 0, 1, 12, 24, or 36h. Levels of
phosphorylated Smad1/5/8 in cell extracts were determined
using an antibody (Ab) speciﬁc for the phosphorylated
C-terminal region of Smad1/5/8 (pSmad1/5/8-CT). We found
that pSmad1/5/8-CT levels were signiﬁcantly higher and
sustained over time in cells depleted of Bat3 (Figure 2a).
To conﬁrm this ﬁnding in intact cells, we cultured C2C12
shCNT and shBat3 cells with 100ng/ml BMP-2 for 0; 1; 12;
or 24h, ﬁxed the cells, and stained them with anti-pSmad1/5/
8-CTAb(Figure2b).BeforeBMPtreatment,onlytraceamounts
of pSmad1/5/8-CT were present in the cytosol of both shCNT
and shBat3 cells. After 1h of BMP treatment, pSmad1/5/8-CT
levels were markedly increased but appeared equal in the
nuclei of shCNT and shBat3 cells. However, after 12h in BMP-
2, pSmad1/5/8-CT levels were noticeably decreased in
shCNT cells compared with shBat3 cells. After 24h of BMP-
2 treatment, pSmad1/5/8-CT was almost undetectable in
nuclei of shCNT cells but remained clearly visible in nuclei of
shBat3 cells. Quantitation of the signal intensity of nuclear
pSmad1/5/8-CT staining in these cultures conﬁrmed a
signiﬁcant increase in pSmad1/5/8-CT in Bat3-depleted
cells at 12 or 24h post BMP but not at earlier time points
(Figure2c).Thus,Bat3appearstoinﬂuencethetermination
of Smad phosphorylation.
WenextexaminedlevelsofSmad1/5/8-CTphosphorylation
in WT and Bat3
 /  primary osteoblasts cultured with 100ng/
ml BMP-2 for up to 36h. As observed in our Bat3-depleted
C2C12 cells, levels of pSmad1/5/8-CT were higher in BMP-
treated Bat3
 /  osteoblasts than in BMP-treated WT osteo-
blasts (Figure 2d). Moreover, the reintroduction of Bat3–Myc
intoshBat3U2OScells(SupplementaryFigure1C)resultedin
lower levels of pSmad1/5/8-CT compared with those in empty
vector-transfected shBat3 U2OS cells (Figure 2e). Last, Bat3
depletion in the U2OS also resulted in sustained Smad
phosphorylation (increased pSmad1/5/8-CT) upon BMP
treatment (Supplementary Figure 1D). Taken together, our
data clearly indicate that Bat3 promotes the termination of
Smad1/5/8 phosphorylation in response to BMP signaling.
Bat3 forms a complex with SCP nuclear phosphatases
and enhances SCP2–Smad1 interaction. Our data
showed that the induction of BMP target genes was
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Cell Death and Diseaseunaffected by Bat3 deﬁciency at early time points but
signiﬁcantly increased at later time points (Figure 1). In
addition, Smad phosphorylation was abnormally prolonged in
the absence of Bat3 (Figure 2). We therefore speculated that
Bat3’s physiological function might be to regulate Smad1/5/8
dephosphorylation. Among the Smad phosphatases, the
SCPs, which are nuclear enzymes, have been shown to
dephosphorylate Smad1/5/8 at the C terminus and thus
attenuate BMP signaling.
26 Accordingly, previous reports
have demonstrated that depletion of SCP2 enhances BMP
signaling,
26 and that SCPs thus positively regulate TGF-b
signaling.
8,26 These ﬁndings prompted us to explore whether
Bat3 was functionally connected to SCPs.
We ﬁrst tested whether Bat3 could interact with SCP1, 2, or 3
in 293T cells. Co-immunoprecipitation (IP) analysis revealed
that Bat3–Myc clearly associated with SCP1 or SCP2 at
comparable levels but bound only very weakly to SCP3
(Figure 3a). In addition, recombinant Bat3 and SCP2 proteins
interacted (Supplementary Figure 7). We then determined
whether Bat3 could interact with the Smurfs and/or I-Smads,
which negatively regulate BMP signaling by binding to Smad6
and Smad7, respectively. However, Bat3 did not bind to either
Smurf1 or Smurf2, or Smad6 or Smad7 (Figure 3b). Previous
work has shown that, although SCP1 and SCP2 show
similar enzymatic activities when overexpressed, only SCP2
inactivation inhibits TGF-b signaling and enhances BMP
Figure 1 Loss of Bat3 potentiates BMP signaling. (a) Bat3 suppresses Id1 promoter activity. U2OS cells were transiently transfected with an Id1–luc plus the indicated
combination of Bat3–Myc and HA-tagged constitutively active (QD) ALK2, 3, and 6 expression vectors. Results are Id1–luc values normalized using Renilla luciferase activity
underthecontrolofthecytomegaloviruspromoter.(b)ProlongedinductionofBMPtargetgenesinBat3-depletedcells.C2C12cellsweretransfectedwithsiCNTorsiBat3,and
treated with 100ng/ml BMP-2 for the indicated times. Transcript levels of the indicated genes were measured by quantitative RT-PCR and normalized to hypoxanthine
phosphoribosyltransferase 1 expression. (c) Prolonged induction of BMP target genes in BMP-treated Bat3
 /  osteoblasts. Primary osteoblasts from WT and Bat3
 /  mice
weretreatedwith 100ng/ml BMP-2for the indicatedtimes.Transcript levels of the indicatedgenes wereanalyzedas in b. For a, resultsare themean±S.D. of triplicatesand
are representative of three trials. For b and c, results are the mean±S.D. of duplicates and are representative of three trials. **Po0.01 and *Po0.05
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8,26 Indeed, we found that SCP2 overexpression
reduced Smad1/5/8 phosphorylation induced by ALK6-QD
(Supplementary Figure 2). We therefore focused the rest of
our study on Bat3’s interaction with SCP2.
First, we examined whether Bat3 inﬂuenced SCP2’s
negative regulatory effects on Id1 promoter activity. We
co-transfected U2OS cells with the Id1–luc reporter
construct plus vectors expressing ALK3-QD and increasing
amounts of SCP2 and Bat3–Myc (Figure 3c). Consistent
with previous reports,
8,26 SCP2 suppressed Id1 promoter
activity in a dose-dependent manner in the absence of
Bat3. Moreover, consistent with our Figure 1 data, we
found that, as the Bat3 level increased, the promoter
suppression mediated by SCP2 was enhanced. These
ﬁndings suggest that a functional interaction occurs between
Bat3 and SCP2.
Figure 2 Bat3 negatively regulates Smad1/5/8 phosphorylation upon BMP treatment. (a) Sustained C-terminal phosphorylation of Smad1/5/8 (pSmad1/5/8-CT) in
Bat3-depleted cells. C2C12 cells infected with lentivirus expressing shCNT or shBat3 were cultured in the presence of 100ng/ml BMP-2 for the indicatedtimes. Lysates were
immunoblotted to detect the indicated proteins. Tubulin was used as the loading control. (b) Nuclear pSmad1/5/8-CT, shCNT, and shBat3 C2C12 cells were treated with
100ng/ml BMP-2 for the indicated times. Cells were ﬁxed in ice-cold ethanol and stained with anti-phospho Smad1/5/8 Ab, followed by anti-rabbit IgG (red). Nuclei were
visualized by Hoechst 33258 (blue). (c) Quantitation of nuclear pSmad1/5/8 staining in b. FluoView software was used to measure the pixel intensity of pSmad1/5/8 staining
thatco-localizedwithHoechst33258stainingineachnucleusandshownaspercentage.Resultsarethemean±S.D.of30cellsperﬁeldfor3ﬁelds.(d)SustainedC-terminal
phosphorylation of Smad1/5/8 in Bat3
 /  osteoblasts. WT and Bat3
 /  osteoblasts were treated with 100ng/ml BMP-2 for the indicated times. Lysates were immunoblotted
to detect the indicated proteins as for a.( e) Reintroduction of Bat3 allows resumption of Smad1/5/8 dephosphorylation in U2OS cells. U2OS cells depleted for Bat3 were
transfected with control vector or Bat3–Myc vector. Transfected cells were treated with 25ng/ml BMP-2 for the indicated times and immunoblotted to detect the indicated
proteinsas for d.Note that thedoubletband for pSmadsis a celltype-speciﬁcphenomenon andwas observedonly inU2OS cells. For a–e, resultsare representative of three
trials. Full-length blots are presented in Supplementary Figure 5
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tested whether Bat3 inﬂuences Smad1–SCP2 binding. We
co-transfected 293T cells with tagged vectors expressing
Smad1, SCP2, and increasing amounts of Bat3 in the
presence or absence of ALK6-QD, and examined Smad1–
SCP2 interaction by IP (Figure 3d). Bat3 overexpression
did not inﬂuence Smad1–SCP2 binding in the absence of
ALK6-QD.However,inthepresenceofALK6-QD,Smad1–SCP2
interaction was markedly enhanced by Bat3 addition. These
data indicate that Bat3 promotes the interaction of SCP2 with
the active form of Smad1, and enhances SCP2’s subsequent
dephosphorylation activity. Thus, our ﬁndings constitute
additional evidence that Bat3 contributes to the processes
terminating BMP signaling.
Bat3 inactivation enhances bone differentiation. To
determine whether Bat3 inﬂuences biological responses to
BMP, we used bone differentiation as an experimental
readout. We cultured C2C12 cells expressing siCNT or
siBat3 with 100ng/ml BMP-2 for 3, 24. or 48h and examined
the transcript levels of the bone differentiation markers
Runx2, Osterix, and alkaline phosphatase (ALP). Induction of
these markers was comparable in control and Bat3-depleted
cells up to the 24h time point (Figure 4a). However, levels of
these differentiation markers were signiﬁcantly higher in the
absence of Bat3 after 48h BMP-2 treatment. Similar results
were obtained for BMP-2-treated Bat3
 /  osteoblasts
compared with BMP-treated WT osteoblasts (Figure 4b).
Next,weexaminedALPenzymaticactivityinBat3-depleted
C2C12 cells (shBat3 cells) and Bat3
 /  osteoblasts. Con-
sistent with our gene expression analyses, Bat3 inactivation
markedly enhanced ALP induction in both cell types (Figures
4c and d). Last, BMP-6-treated Bat3
 /  mouse embryonic
ﬁbroblasts (MEFs) showed the same pattern of elevated
pSmad1/5/8, enhanced ALP induction, and increased ALP
activity as Bat3
 /  osteoblasts (Supplementary Figure 3).
Taken together, these data point clearly to a role for Bat3 in
biological responses to BMP.
Discussion
It is well established that the level and duration of R-Smad
activity has critical effects on TGF-b-induced transcriptional
responses.
27 It is therefore logical that pathways that regulate
Figure 3 Bat3 interactswith SCPsandenhancestheirfunctions.(a)BindingofBat3 toSCPs. 293Tcellsweretransfectedwith Bat3–Mycplusemptyvector( ) orFLAG-
taggedSCP1,SCP2,or-CP3,asindicated.At24hposttransfection,lysateswereimmunoprecipitatedusinganti-FLAGbeadsandimmunoblottedanti-Myc–HRPAb.(b)Bat3
does not interact with Smurfs or I-Smads. 293T cells were transfected with Bat3–Myc plus FLAG–SCP2, FLAG–Smurf1 or –Smurf2, or FLAG–Smad6 or –7, as indicated.
Lysates were immunoprecipitated and immunoblotted as for a.( c) Bat3 enhances SCP2-mediated suppression of Smad transcriptional activity. 293T cells were transfected
withtheindicatedcombinationsofId1–lucplustaggedALK3-QD,Bat3,andSCP2expressionvectors.DatawereanalyzedasforFigure1a.(d)Bat3enhancesSCP2–Smad1
interaction upon activation of BMP signaling. 293T cells were transfected with tagged Smad1, SCP2, and/or ALK6-QD vectors plus increasing amounts of Bat3–Myc. At 24h
post transfection, lysates were immunoprecipitated with anti-FLAG beads and immunoblotted with anti-HA Ab. For a–d, results are representative of at least three trials.
Full-length blots are presented in Supplementary Figure 6
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Cell Death and Diseasethe dephosphorylation inactivating R-Smads would have a
signiﬁcant impact on TGF-b and BMP signaling. Although
multiple Smad phosphatases have been identiﬁed,
28 it has
been unclear how the activity and expression of these
phosphatases are regulated. In this study, we have shown
that Bat3 promotes Smad1/5/8 dephosphorylation and there-
by inﬂuences BMP signaling. In addition, we have started to
unravel the molecular mechanisms underlying this regulation.
The regulation of R-Smad dephosphorylation has been
difﬁcult to dissect, partly because of the diverse and dynamic
functions of these phosphatases, and partly because of our
poor understanding of the tissue-speciﬁc mechanisms that
control these enzymes.
29 Among the known Smad phospha-
tases, the SCPs have been reported to differentially regulate
Smad2/3 and Smad1/5/8.
7,8,26 SCP1 and 2 clearly dephos-
phorylate the linker regions of Smad2 and 3, thereby
Figure 4 Bat3 inactivation enhances bone differentiation. (a) Increased expression of bone differentiation markers in the absence of Bat3. C2C12 cells were transfected
with siCNT or siBat3 and treated with 100ng/ml BMP-2 for the indicated times. Transcript levels of the indicated bone differentiation markers were determined by qPCR.
Results were analyzed as for Figure 1b. Results are the mean±S.D. of duplicates and are representative of three trials. **Po0.01 and *Po0.05. (b) Enhanced induction of
bone differentiation markers in Bat3
 /  osteoblasts. WT and Bat3
 /  osteoblasts were treated with BMP-2 for the indicated times. Transcript levels of the indicated markers
wereanalyzedas for a. Resultsare themean±S.D. of duplicatesandare representativeof three trials.**Po0.01and *Po0.05.(c and d) Enhancedinductionof ALP in the
absence of Bat3. (c) shCNT and shBat3 C2C12 cells were treated with 30ng/ml BMP-2 for 48h, and (d) WT and Bat3
 /  osteoblasts were treated with 100ng/ml BMP-2 for
48h.Inbothcases,levelsofALPactivityweremeasuredinsituusingaplatestainingassaywithp-nitrophenylphosphateasthesubstrate.Toppanels:absorbanceinextracts
of plated cells was normalized to protein concentration. All measurements are relative to time zero (set to one). Bottom panels: representative images of stained plates
showing ALP activity. For c, results are the mean±S.D. of duplicates and are representative of three trials. For d, results are the mean±S.D. of triplicates and are
representative of two trials. **Po0.01
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Cell Death and DiseaseenhancingTGF-bsignaling.However,controversyexistsover
whether SCP-mediated dephosphorylation of sites within the
linker and C-terminal regions of Smad1 can inactivate this
molecule,thereby suppressing BMP signaling.
7,8,26 Our study
has partially resolved this issue by demonstrating that SCP2
can indeed dephosphorylate the C-terminal phosphorylation
sites in Smad1 and Smad5, while showing weaker activity for
Smad8 (Supplementary Figure 2). It is currently unknown
whether SCPs require additional factors and/or modiﬁcations
to initiate Smad1 dephosphorylation, or whether SCP-
mediated Smad1 dephosphorylation is tissue or species
speciﬁc. Nevertheless, our data indicate that Smad1–SCP2
interaction is enhanced by Bat3, and that this series of events
regulates BMP signaling (Figure 3).
Bat3 has been reported to act as a regulator of molecular
chaperone proteins,
30 and also contains a ubiquitin-like (UBL)
domain. Therefore, like other UBL-containing proteins,
31 Bat3
may suppress or enhance protein stability, protein–protein
interactions,or both.Although Bat3targetproteinshave yetto
be fully delineated, our biochemical analyses indicate that
SCP2 is a Bat3-interacting protein. Interestingly, Bat3
enhances Smad1–SCP2 interaction only in the presence of
constitutively active ALK6 (Figure 3). It has been previously
shown that ALK5–Bat3 interaction accelerates the transloca-
tionofBat3intothenucleus.
22However,inthecontextofBMP
signaling, we were unable to detect any interaction between
Bat3 and ALK2, 3, or 6 (Supplementary Figure 4). In addition,
Bat3 is located predominantly in the nucleus in the cell lines
used in our study, obscuring any increase in levels of total
Bat3 protein or nuclear Bat3 protein that might have been
induced by BMP treatment (Figure 2, Supplementary Figure 1
and data not shown). Finally, although our data strongly
suggest that Bat3 enhances the interaction between SCP and
phosphorylated Smad1, it remains to be elucidated whether
additional post-translational modiﬁcations (e.g., ubiquitination
or acetylation) of Smad1, SCP2, and/or Bat3 are required for
physiological regulation of BMP signaling.
In their detailed analyses of the developmental defects of
Bat3-deﬁcient mice, Desmots et al.
15 reported that these
mutants showed impaired branching of the terminal bron-
chiolar alveoli in the lung as well as abnormal renal branching
inthekidney,twoprocessesforwhichBMPsignalingisknown
to be crucial.
32–34 These in vivo ﬁndings raised the possibility
that dysregulated BMP signaling might be responsible for the
defects in their Bat3-deﬁcient mice. Our demonstration in cell
lines that Bat3 inactivation sustained BMP signaling and
enhances osteoblast differentiation support a role for Bat3 in
development.However,furtherinvestigation oftissue-speciﬁc
Bat3knockoutmicewillberequiredtoconﬁrmanysuchinvivo
functions for Bat3.
In conclusion, our work demonstrates that Bat3 positively
regulates dephosphorylation of Smad1/5/8 and thus functions
as a negative regulator of BMP signaling. As BMPs enhance
bonegeneration,modiﬁcation oftheBMP–Bat3signaling may
improveefﬁcacyofbonereplacementandimplant.Inaddition,
because dysregulation of the TGF-b and BMP signaling
pathways has been observed in numerous human disorders,
including cancer,
32,35,36 it would be interesting to determine
whether mutations of Bat3 are associated with disease
progression.
Materials and Methods
Primary cells from mice. Bat3
 /  mice have been previously described.
17
Primaryosteoblastswereisolatedfromindividualcalvariaofnewborn(P3orP4)WT
and Bat3
 /  mice as previously described.
37 Bat3-deﬁcient and WT MEFs were
prepared from E13.5 embryos using a standard procedure.
38 Primary osteoblasts
were maintained in a-MEM medium, and MEFs were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; both from Invitrogen, Burlington, ON, Canada).
Media were supplemented with 10% fetal bovine serum (FBS; Wisent, ST-Bruno,
QC, Canada), penicillin (100U/ml), and streptomycin (100mg/ml). Cells were
cultured at 371C in a humidiﬁed atmosphere containing 5% CO2.
Celllines. U2OScells,C2C12cells,and293Tcellswereoriginallyobtainedfrom
the American Type Culture Collection (Manassas, VA, USA). U2OS cells were
maintained in McCoy 5A medium, and 293T and C2C12 cells were maintained in
DMEM (both from Invitrogen). Media were supplemented with 10% FBS (Wisent),
penicillin (100U/ml), and streptomycin (100mg/ml). Cells were cultured at 371Ci na
humidiﬁed atmosphere containing 5% CO2.
BMP stimulation. Cellswereseededata densityof 1.0 10
5cellsper wellon
collagen-I-coated 12-well plates and cultured for 24h. The culture medium was
then replaced with 1.0% FBS-containing medium for 4h before the addition of
25–100ng/ml (ﬁnal concentration) of recombinant BMP-2 or BMP-6 (R&D Systems,
Minneapolis, MN, USA) as previously described.
33 After BMP stimulation, cells were
harvested for biochemical or histochemical analyses as described below.
DNA transfection. The constructs expressing Bat3, Smads, or constitutively
active forms of BMP type I receptors (ALKs) have been described previously.
17,24
Cells were transfected with plasmids using FuGENE6 transfection reagent (Roche
Diagnostics,Mississauga,ON, Canada)orLipofectamine2000transfection reagent
(Invitrogen) according to the manufacturer’s recommendations.
siRNA transfection. Synthetic siRNA oligo duplexes for mouse and human
Bat3 were purchased from Dharmacon Inc. (Lafayette, CO, USA). The human Bat3
siRNA oligo-duplex sequence was as previously described,
17 and the mouse Bat3
siRNA oligo-duplex sequence was 50-GAUCUGCGCUGCAAUCUAG-30 or
50-GCACGUGGUUCGGCCUAUG-30. For siRNA-mediated gene silencing, cells
were transfected with siRNA oligo duplexes (ﬁnal concentration, 40nM) using
Hiperfect (Qiagen,Toronto,ON, Canada).All controlsamplesweretransfectedwith
control siRNA oligo duplex (Dharmacon Inc.). At 48h post transfection, the
transfected cells were cultured in 1.0% FBS-containing medium for 4h before BMP
stimulation as above.
Lentiviral shRNA transfection. Target sequences of shRNA were chosen
from siRNA oligos based on their knockdown efﬁciency. Annealed oligos were
subcloned into pLKO.1 (Addgene, Cambridge, MA, USA).
39 For lentivirus
production, 2.5 10
6 HEK-293T cells were plated in a 6-cm tissue culture dish
and transfected with shRNA plasmids using FuGENE6 (Roche Diagnostics)
according to the manufacturer’s protocol. After 24h incubation at 371Ci n5 %C O 2,
the culture medium was replaced with 5ml fresh DMEM containing 10% FBS and
antibiotics. Culture supernatants were harvested after 24h, ﬁltered through a
0.45mm ﬁlter, and used immediately for experiments, or aliquoted and stored in
 801C freezer for subsequent use.
ALP analyses. Histochemical analysis was performed using the ALP staining
kit (no. 85L-3R; Sigma, Oakville, ON, Canada) according to the manufacturer’s
protocol. Quantitative analysis of ALP activity was performed as previously
described,
40 using Sigma Fast p-nitrophenyl phosphate tablet sets (Sigma). The
data were normalized to protein concentration measured by the BCA Protein Assay
Reagent Kit (Pierce, Nepean, ON, Canada) using bovine serum albumin as the
standard. All measurements were relative to time zero, which was set to one.
Luciferase assay. The transcriptional activation induced by constitutively
active ALK (ALK-QD) was measured using Id1–luc reporter constructs.
41 U2OS
cells were seeded in 12-well plates (BD Falcon, Mississauga, ON, Canada) and
transiently transfected with the appropriate combinations of reporter construct and
expression plasmids. At 24h post transfection, cell lysates were prepared, and
luciferase activities were measured by the Dual-Luciferase reporter system
(Promega, Madison, WI, USA) using a luminometer (Turner Biosystems
Luminometer, Promega). Values were normalized using Renilla luciferase activity
under the control of the cytomegalovirus promoter.
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bufferconsistingof150mMNaCl,50mMTris-HCl(pH7.4),1%NonidetP-40,1mM
phenylmethylsulfonyl ﬂuoride (PMSF), and protease inhibitor cocktail (Roche
Diagnostics). Lysates were centrifuged and supernatants were incubated with the
appropriate antibodies at 41C for 16h with rotation. For immune complex isolation,
lysate–Ab mixtures were incubated for an additional 0.5–1h with protein
A/G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) before
fractionation. Immune complexes or immunoprecipitates were fractionated by SDS-
PAGE and subjected to immunoblotting using standard procedures.
For protein analysis, samples were prepared in RIPA lysis buffer consisting of
1% Nonidet P-40, 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM EDTA (pH 8.0),
0.5% sodium deoxycholate, 0.1% SDS, 2mM NaF, protease inhibitor cocktail
(Roche Diagnostics), and 1mM PMSF.
Antibodies recognizing the following proteins were used: Smad1/5/8
(N-18; Santa Cruz Biotechnology), Smad1 (Invitrogen), phospho-Smad1/5/8 (Cell
Signaling, Pickering, ON, Canada), Flag (M2; Sigma), Myc (Sigma), a-tubulin
(DM1A; Sigma), b-actin (Sigma), and HA (Roche Diagnostics). Anti-Bat3 Ab has
been previously described.
17
Quantitative real-time reverse transcription PCR. Total RNA was
extracted from C2C12 cells or primary osteoblasts using the RNeasy plus Mini Kit
(Qiagen). cDNA was synthesized using SuperScript III reverse transcriptase
(Invitrogen), followed by PCR speciﬁc for target genes (primer sequences are listed
in Supplementary Table S1 in Supplementary Information). Real-time PCR was
performed using Power SYBR Green PCR Master Mix (Applied Biosystems,
Streetsville, ON, Canada), and data were collected using the ABI Prism 7900HT Fast
Real-time PCR system (Applied Biosystems). The speciﬁcity of the detected signals
was conﬁrmed by observation of a dissociation curve containing a single peak. Data
were normalized to expression levels of hypoxanthine phosphoribosyltransferase 1.
Immunoﬂuorescent microscopy. Cells were ﬁxed in ice-cold 100%
ethanol at0, 1,12, and 24h post BMP treatment for 15min at  201C and blocked in
CAS-BLOCK (Invitrogen) for 10min at room temperature. Slides were incubated with
rabbit anti-phospho-Smad1/5/8 (Cell Signaling) as the primary Ab, followed by Alexa
Fluor 594 goat anti-rabbit IgG (Invitrogen). Hoechst 33258 (Invitrogen) was used to
stain DNA. Images were acquired on an Olympus (Richmond Hill, ON, Canada) IX81
and FluoView FL1000 confocal microscope using a  63/1.2 NA water immersion
objective.Hoechst33258andAlexa594signalswereimagedsequentiallyusing351-
and 543-nm laser excitation and the appropriate band-pass emission ﬁlters.
Production of recombinant proteins. Escherichia coli (BL21 (DE3))
transformedwithGSTorGST–SCP2werelysedwithRIPAbuffer(50mMTris-HCl,pH
8.0, 150mM NaCl, 1mM EDTA, 1mM DTT, 1mM PMSF, protease inhibitor cocktail
(Roche Diagnostics), and 1% Triton-X 100 for 30min on ice and sonicated three times
for 30s on ice. Cell lysates were cleared by centrifugation at 4150 g for 60min at
41C.Lysateswereincubatedwith100mlof50%slurryofglutathioneSepharose4Fast
Flow (GE Healthcare Life Sciences, Baie d’Urfe, QC, Canada) for 1 or 2h at 41C with
end-over-end rotation. The glutathione beads were then collected by centrifugation at
2500 gfor 2minat 41Cand washed ﬁve times withice-coldPBS. Overexpressionof
6  His-tagged recombinant protein Bat3 was puriﬁed by Ni-NTA column (Qiagen)
according to the manufacturer’s instructions. Each sample was conﬁrmed by GelCode
Blue Stain Reagent (Thermo Scientiﬁc, Nepean, ON, Canada).
GSTpulldownassay. PuriﬁedBat3–Hislysates(500ml) wereincubatedwith
100ml of a 50% slurry of GST or GST–SCP2 binding glutathione Sepharose 4 Fast
Flow for 4h at 41C with rotation. The bound proteins were then released by boiling
for 3min at 981Ci n1  SDS-PAGE sample buffer for subsequent immunoblot
analysis. Ab used was anti-GST Ab (GE Healthcare Life Sciences).
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